Clinical trials: Plasma Cell Tumor
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00060346
- Testing
- rituximab, cyclophosphamide, Doxorubicin
- Where
- 153 sites in United States
- Volunteers
- 16 people
- Sponsor
- Eastern Cooperative Oncology Group
Multiple Myeloma, Stem Cell Transplantation
Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma
To evaluate the feasibility and efficacy of a autologous stem cell transplantation followed by a Melphalan/ Fludarabine based dose-reduced allograft from HLA-identical and HLA-compatible unrelated donor in patients with Multiple…
- Trial name
- NCT00781170
- Testing
- allogeneic hematopoietic SCT
- Volunteers
- 20 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma
This phase I trial studies how well vismodegib after stem cell transplant works in treating patients with high-risk first remission or relapsed multiple myeloma. Vismodegib may slow the growth of cancer cells.
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01330173
- Testing
- Vismodegib, Pharmacological Study, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Lymphoma, Non-Hodgkin
AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF
This study evaluates the safety and efficacy of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients with…
- Trial name
- NCT00396266
- Testing
- G-CSF Plus Plerixafor
- Where
- 2 sites in Canada
- Volunteers
- 22 people
- Sponsor
- Genzyme, a Sanofi Company
Carcinoma, Non-Small-Cell Lung
Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer
Genetic rearrangements in the Anaplastic Lymphoma Kinase (ALK) gene result in the creation of a variety of oncogenic fusion proteins that drive malignancy in a subset of non-small cell lung cancers (NSCLC) patients.
- Trial name
- NCT02718651
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- University of Aarhus
Cancer, Adult Solid Tumor
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials.
- Conditions
- Cancer, Adult Solid Tumor, Lymphoma, Multiple Myeloma
- Trial name
- NCT03061305
- Where
- 40 sites in United States
- Volunteers
- 58,213 people
- Sponsor
- Strata Oncology
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
To see if it is possible to use short-duration tacrolimus after a peripheral blood stem cell transplant in certain malignancies that are considered difficult to engraft.
- Conditions
- Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT02556931
- Testing
- Fludarabine, Cyclophosphamide, Total body irradiation
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
The work proposed herein aims to provide the first prospective, randomized comparative efficacy data between Melphalan and BEAM treatment regimen in the Multiple Myeloma (MM) patient population.
- Trial name
- BEAM (NCT03570983)
- Testing
- Allopurinol, Carmustine, Etoposide
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Swedish Medical Center
Quality of Life, Multiple Myeloma
Quality of Life the Danish Multiple Myeloma Patients
The aim of the project is to improve quality of life for multiple myeloma patients in the future.
- Trial name
- QoL-MM (NCT02892383)
- Where
- 10 sites in Denmark
- Volunteers
- 681 people
- Sponsor
- Odense University Hospital
Myeloma
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
The purpose of the study is to evaluate the effect of Elranatamab therapy after cilta-cel measuring how long a patient with high risk relapsed myeloma lives without the myeloma getting worse(progressing), also known as…
- Trial name
- NCT06947083
- Testing
- Elranatamab
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
MMRF CureCloud Research Initiative
The MMRF CureCloud Research Initiative, a Direct-to-Patient Research effort aimed at enrolling 5,000 individuals from whom comprehensive molecular and immune analyses will be generated from blood specimens and the resulting data…
- Trial name
- NCT03657251
- Testing
- liquid biopsy
- Where
- 4 sites in United States
- Volunteers
- 1,105 people
- Sponsor
- Multiple Myeloma Research Foundation
Refractory Multiple Myeloma, Smoldering Multiple Myeloma
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
RATIONALE: Melphalan, a chemotherapeutic agent, has been found to be an effective treatment choice for destroying myeloma cells, especially when given at high (bone marrow ablative) doses.
- Conditions
- Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma
- Trial name
- NCT00112827
- Testing
- total marrow irradiation, melphalan, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
The study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in patients with untreated…
- Trial name
- NCT01731886
- Testing
- Autologous peripheral blood stem cell transplant, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Columbia University
Leukemia, Lymphoma
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00003402
- Testing
- carmustine, cisplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Maryland, Baltimore
Multiple Myeloma
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.
- Trial name
- ENDEAVOR (NCT01568866)
- Testing
- Carfilzomib, Bortezomib, Dexamethasone
- Where
- 241 sites in United States, Australia and 25 more
- Volunteers
- 929 people
- Sponsor
- Amgen
Multiple Myeloma
Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
For each subject the study will consist of two phases: a treatment phase and a follow-up phase. Screening procedures will take place within 28 days of baseline.
- Trial name
- NCT00065351
- Testing
- CC-5013
- Where
- 26 sites in United States
- Volunteers
- 222 people
- Sponsor
- Celgene
Relapsed/Refractory, Multiple Myeloma
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
This study is a single-centre, single-arm, open-label, dose-escalation exploratory study with single-dose administration. Its objective is to evaluate the safety, tolerability, dose, anti-tumor efficacy, and pharmacokinetic…
- Trial name
- NCT06999031
- Testing
- BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- The First Affiliated Hospital of Nanchang University
Multiple Myeloma
A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat
This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with…
- Trial name
- RECOMM (NCT04150289)
- Testing
- Farydak
- Where
- 7 sites in United States
- Volunteers
- 248 people
- Sponsor
- pharmaand GmbH
Multiple Myeloma
Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.
This is a multicenter, phase II, national, and open-label study to evaluate the efficacy and safety of two different combinations, iberdomide-dexamethasone (IBERDEX) and iberdomide-dexamethasone in combination with daratumumab…
- Trial name
- NCT05527340
- Testing
- Iberdomide, Dexamethasone, Daratumumab
- Where
- 9 sites in Spain
- Volunteers
- 140 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma
A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in participants with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT04394650
- Testing
- CC-98633
- Where
- 11 sites in United States
- Volunteers
- 78 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.